|
Mus musculus-PrxI |
(66) |
malignant cancers,
hemolytic
anemia, premature death |
|
M. musculus-PrxI |
(58) |
increased DNA oxidation,
increased c-Myc activation in embryonic fibroblasts |
|
M. musculus-PrxI |
(65) |
increased susceptibility
to Ras-induced breast cancer |
|
M. musculus-PrxII |
(59) |
increased protein oxidation
in red blood cells, hemolytic anemia |
|
M. musculus-PrxII |
(67) |
increased plaque formation,
predisposition to develop atherosclerosis |
|
M. musculus-PrxII |
(69) |
enlarged thymus, increased
T cell proliferation |
|
M. musculus-PrxII |
(68) |
increased splenocytes, bone
marrow differentiation |
|
M. musculus-PrxII |
(71) |
increased p21 and p53 levels,
increased cellular senescence |
|
M. musculus-PrxII |
(60) |
increased protein cysteine
oxidation in red blood cell fractions |
|
M. musculus-PrxIII |
(61) |
increased lung
damage from
inflammation, increased DNA damage |
|
M. musculus-PrxIII |
(62) |
increased fat mass,
increased
protein carbonylation in adipose tissue |
|
M. musculus-PrxIII |
(72) |
reduced litter
size, increased
oxidative stress in placenta tissue |
|
M. musculus-PrxIII |
(73) |
increased macrophage
apoptosis
by lipopolysaccharide treatment |
|
M. musculus-PrxIV |
(74) |
testicular atrophy, reduced
sperm viability in oxidative stress |
|
M. musculus-PrxVI |
(134) |
increased lung damage, decreased
animal survival due to hyperoxia |
|
M. musculus-PrxVI |
(131) |
increased ischemic reperfusion
injury, increased cardiomyocyte apoptosis |
|
M. musculus-PrxVI |
(135) |
decreased lung surfactant
degradation |
|
M. musculus-PrxVI |
(64) |
increased LDL oxidation
by macrophages, increased plasma lipid H2O2 levels |
|
M. musculus-PrxVI |
(136) |
increased UPR, increased
apoptosis in lens epithelial and aging cells |
